PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Randox Laboratories Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Randox Introduces Innovative Multi-marker DoA Testing Procedure - Randox have developed an innovative multi-marker drugs of abuse (DoA) testing procedure for rapid drug screening programmes
Randox Introduces Innovative Multi-marker DoA Testing Procedure

 

NewswireToday - /newswire/ - Crumlin, Antrim, United Kingdom, 2009/11/24 - Randox have developed an innovative multi-marker drugs of abuse (DoA) testing procedure for rapid drug screening programmes.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The Drugs of Abuse (DoA) biochips permit the analysis of up to 10 drug classes from a single patient sample providing rapid and accurate testing.

Randox biochip array technology (randox.com) is based on tried and tested ELISA methods. Each 9x9mm biochip comprises up to 25 discrete test regions (DTRs) on which immobilised antibodies specific to each biomarker are contained. In addition, two DTRs are reserved for quality control testing. The Drugs of Abuse biochip arrays demonstrate superior assay performance and also show excellent correlation with GC/MS.

Two Drugs of Abuse biochip arrays are available; DoA array I contains, amphetamine, methamphetamine, barbituates, benzodiazepine 1 & 2, Cannabinoids, cocaine metabolite, methadone, opiates and phencyclidine. DoA array II enables testing for buprenorphine, fentanyl, generic opioids, ketamine, LSD, MDMA, methaqualone, oxycodone 1 & 2 and propoxyphene. As a further feature, creatinine is included on the arrays as a marker of adulteration when testing urine samples. Both biochip arrays are validated for use with urine and whole blood. The use of oral fluid as a sample matrix is validated on DoA array I and currently in development for DoA array II.

Three revolutionary biochip analysers have been developed and can be employed for the Drugs of Abuse arrays. The fully automated Evidence was designed for high throughput laboratories and requires as little as 7µl of urine for all 10 drug classes. This rapid testing platform generates 1088 tests per hour. Once samples are loaded onto the Evidence, the doors are locked and the PC interface is password protected providing chain of custody information. The semi-automated Evidence Investigator for medium size labs and the point of application Evidence MultiStat analyser which generates results in 20 minutes are also available.

The revolutionary Randox Drugs of Abuse biochip array technology will ensure accurate and rapid drug screening guaranteeing confidence in results and ultimately saving valuable time and reducing costs.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Randox Laboratories Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Medical Services/Equipment articles,
CATCH Visitors via Your Competitors Announcements!


Randox Introduces Innovative Multi-marker DoA Testing Procedure

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Charlotte Jess - Randox.com 
+44(0)28 4245 7832 marketing[.]randox.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Randox Laboratories Ltd securities in any jurisdiction including any other companies listed or named in this release.

Medical Services/Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Randox Laboratories Ltd / Company Profile


Read Medical Services/Equipment Most Recent Related Newswires:

Frost & Sullivan Lauds ClearFlow’s ACT® Technology as a Transformational Force in Post-operative Cardiothoracic Surgery Protocols
ZOLL Receives Health Canada Approval for Two New Models of AEDS
ZOLL Hospital Wearable Defibrillator Receives Premarket Approval from the FDA
AFC Industries Joins HIMSS for its 56th Edition
Medical Companies Flock to Israel for R&D Support Infrastructure and Inorganic Growth Opportunities Finds Frost & Sullivan
GE Healthcare Expands MRI Contrast Media Product Range in Europe with Launch of Macrocyclic Agent Clariscan
Sparta Systems Launches Product Registration Tracking for 123Compliance Cloud QMS
Frost & Sullivan Lauds SnooZeal’s Unique Electrical Stimulation Therapy for Sleep Apnea in the European Market
ZOLL Expands the Rescuer Experience at EMS Today
Traditional Mass Spectrometers Give Way to High-resolution Technologies Such as MALDI-TOF Finds Frost & Sullivan
AccuVein, Inc. Named A Best Place to Work in Medical Sales for Second Consecutive Year
MRI Inventor to Receive the Medtech Innovation Catalyst Award
Ansell Limited Acquires Cleanroom and Healthcare Consumables Manufacturer Nitritex Limited
ZOLL to Showcase Expanded Portfolio of Advanced Resuscitation and Acute Critical Care Technologies at Arab Health 2017
Frost & Sullivan Awards Ansell for Entrenching itself in the Hand Protection Market with its Visionary Products and Technologies

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  MagLar, Inc.

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)